GO
Loading...

Merck & Co Inc

More

  • My Merck/Schering-Plough Coverage Draws Your Emails Friday, 4 Apr 2008 | 5:02 PM ET

    This week started out with Merck shares suffering their worst loss since the day the drugmaker recalled Vioxx and Schering-Plough shares posting their worst one-day decline ever. But yesterday, SGP had its biggest percentage gain in eight years and today it's finishing the week as the sector's biggest percentage gainer.

  • Merrill News Helps Keep Stocks Afloat Thursday, 3 Apr 2008 | 4:51 PM ET

    Stocks logged another lackluster session Thursday in the wake of Tuesday's spectacular rally as the market digested a mixed bag of economic data and a congressional hearing on the Bear Stearns bailout.

  • Rally Fizzles as Oil Creeps Up Near $105 Wednesday, 2 Apr 2008 | 5:02 PM ET

    Stocks finished slight lower Wednesday as the financial-driven rally that kicked off the quarter Tuesday lost steam. Energy, retail and chips finished mostly higher.

  • Vytorin Battle Pits Merck/Schering-Plough Vs Pfizer Tuesday, 1 Apr 2008 | 11:03 AM ET

    Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.

  • Schering CEO Speaks on Vytorin Monday, 31 Mar 2008 | 6:59 PM ET

    "We stand behind our product," Fred Hassan says. But does Cramer?

  • Stocks Gain On Last Day Of Worst Quarter In 5 Years Monday, 31 Mar 2008 | 6:29 PM ET

    Investors bid the Dow higher as the price of oil and other commodities declined. The rally caps a negative quarter for all the major averages. What's the "Word on the Street?"

  • Stocks End on High Note But Quarter Is Sour Monday, 31 Mar 2008 | 5:17 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Vytorin Fallout Monday, 31 Mar 2008 | 4:42 PM ET

    Shares of Merck and Schering-Plough are both under the weather Monday after a study said their Vytorin cholesterol drug isn't any better than a generic. Who wins and who loses?

  • Celebrex risky in high-risk heart patients,  study finds

  • Financials Lead Rebound; Merck Skids Monday, 31 Mar 2008 | 2:16 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Drug Stock Scorecard: MRK, SGP Losers--Pfizer A Winner Monday, 31 Mar 2008 | 11:35 AM ET

    Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.

  • Merck, Schering Shares Hit by Cholesterol Drug Fallout Monday, 31 Mar 2008 | 11:30 AM ET

    Shares of Schering-Plough and Merck tumbled on Monday after doctors at a prominent medical meeting recommended patients try older cholesterol drugs before the companies' newer medicines.

  • Stocks Are Mixed; Merck Drags on Dow Monday, 31 Mar 2008 | 11:23 AM ET

    Stocks opened mixed Monday as the market was on track for its worst quarter in 5 1/2 years and investors looked for insight into the second quarter.

  • AstraZeneca is stopping a clinical trial of its blockbuster cholesterol fighter Crestor early because of the clear benefits of the medicine compared to placebo, the company said on Monday.

  • Paulson Proposal A Bit "Mind-Less" For Markets Monday, 31 Mar 2008 | 9:08 AM ET

    In theory, Treasury Secretary Paulson's announcement that he wants to shake up the regulatory environment on Wall Street is the main news.

  • Yoda

    Yoda made an appearance at the American College of Cardiology (ACC) conference here in Chicago on Sunday. At the end of his speech in the opening session, the outgoing president of the organization played a "Star Wars" clip with the sage saying, "Try not. Do or do not. There is no try." He was trying to make a point about the ACC's role in forging healthcare reform.

  • Vytorin Expert Panel Says 'Go Back to Statins' Sunday, 30 Mar 2008 | 8:18 PM ET

    In the absence of evidence that the cholesterol fighter Vytorin works better than a cheaper drug known as a statin, patients should turn back to using statins and other proven drugs, an expert panel said on Sunday.

  • Vytorin Heart Study Expanded; Results Delayed Friday, 28 Mar 2008 | 5:30 PM ET

    U.S. researchers said on Friday they plan to expand the size of a major study to determine the heart benefits of the controversial cholesterol fighter Vytorin, which they said would delay results until 2012.

  • I don't know how I missed this one, but the Wall Street Journal's Health Blog didn't forget that this week that Pfizer and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill.

  • Friday Trades: Tech, Pharma and Education Friday, 28 Mar 2008 | 2:56 PM ET

    Ahead of the weekend, CNBC asks the experts where investors should place their bets.